Reata Pharmaceuticals

How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Friedreich’s ataxia
Flag link:
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Motley Fool
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Flag link:
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Motley Fool
Biogen
Reata Pharmaceuticals
M&A
Flag link:
Biogen to acquire rare disease drugmaker Reata for $7.3B
Biogen to acquire rare disease drugmaker Reata for $7.3B
BioPharma Dive
Biogen
Reata Pharmaceuticals
M&A
Friedreich's Ataxia
Flag link:
Biopharma stocks go back to bleak
Biopharma stocks go back to bleak
EP Vantage
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Flag link:
FDA Approves First Therapy for Friedreich's Ataxia
FDA Approves First Therapy for Friedreich's Ataxia
BioSpace
Reata Pharmaceuticals
FDA
Friedreich's Ataxia
Flag link:
FDA scraps AdComm for Reata's rare disease candidate, leaving analysts squinting at the tea leaves
FDA scraps AdComm for Reata's rare disease candidate, leaving analysts squinting at the tea leaves
Fierce Biotech
Reata Pharmaceuticals
omaveloxolone
FDA
Friedreich's Ataxia
Flag link:
Reata’s ‘regulatory concerns’ turn into three-month delay on FDA decision for Friedreich’s ataxia drug
Reata’s ‘regulatory concerns’ turn into three-month delay on FDA decision for Friedreich’s ataxia drug
Endpoints
Reata Pharmaceuticals
Friedreich's Ataxia
FDA
omaveloxolone
Flag link:
FDA regulatory roundup: two approvals, three rejections & one clinical hold
FDA regulatory roundup: two approvals, three rejections & one clinical hold
MedCity News
FDA
JNJ
CTI BioPharma
Gilead Sciences
Amryt Pharma
Reata Pharmaceuticals
Flag link:
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed
MedCity News
Reata Pharmaceuticals
Bardoxolone
Alport syndrome
kidney disease
FDA
Flag link:
FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment
FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment
Endpoints
FDA
Reata Pharmaceuticals
Alport syndrome
Flag link:
Reata Pharmaceuticals Sees Hiccup in Filing for Approval of FA Drug
Reata Pharmaceuticals Sees Hiccup in Filing for Approval of FA Drug
BioSpace
Reata Pharmaceuticals
Friedreich's Ataxia
omaveloxolone
Flag link:
Reata Bags $350M As It Preps Rare Chronic Kidney Disease Drug For FDA
Reata Bags $350M As It Preps Rare Chronic Kidney Disease Drug For FDA
Xconomy
Reata Pharmaceuticals
kidney disease
Alport
chronic kidney disease
bardoxolone methyl
Flag link:
Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients
Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients
Reuters
Reata Pharmaceuticals
PAH
clinical trials
COVID-19
Flag link:
Reata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases
Reata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases
Motley Fool
Reata Pharmaceuticals
orphan diseases
omaveloxolone
Flag link:
Reata's bardoxolone offers promise in patients with rare kidney disorder
Reata's bardoxolone offers promise in patients with rare kidney disorder
Endpoints
Reata Pharmaceuticals
Bardoxolone
chronic kidney disease
Alport syndrome
Flag link:
Reata shocks analysts with pivotal win in Friedreich's ataxia
Reata shocks analysts with pivotal win in Friedreich's ataxia
Fierce Biotech
Reata Pharmaceuticals
omaveloxolone
Friedreich's Ataxia
clinical trials
Flag link:
AbbVie Stays Busy While Working to Complete Allergan Acquisition
AbbVie Stays Busy While Working to Complete Allergan Acquisition
BioSpace
AbbVie
Allergan
M&A
Skyrizi
Reata Pharmaceuticals
Flag link:
Reata buys drug rights back from AbbVie for $330M before readout
Reata buys drug rights back from AbbVie for $330M before readout
Biopharma Dive
Reata Pharmaceuticals
AbbVie
bardoxolone methyl
Flag link:
Reata's new CFO on M&A, weathering a recession and biotech's quirks
Reata's new CFO on M&A, weathering a recession and biotech's quirks
Biopharma Dive
Reata Pharmaceuticals
M&A
Manmeet Soni
Flag link:

Pages